Vertex to acquire ViaCyte, with the goal of accelerating its potentially curative VX-880 programmes in Type 1 diabetes. ViaCyte brings tools, technologies and assets with
An international team of scientists led by Anglia Ruskin University (ARU) has announced “extremely positive results” from laboratory trials of a compound that could one
The latest issue of Type 1 Discovery magazine, which aims to give the latest news, events, features and research updates about Type 1 diabetes and
ViCentra is closing its UK operations for the time being due to current supply issues. Two years ago ViCentra withdrew the product from the UK
The BBC has reported that the NHS has been awarded the George Cross by Her Majesty The Queen, accompanied by His Royal Highness The Prince
According to new research at the University of Chicago, the causes of Type 1 diabetes focus on auto-immune response, in which the immune system shatters
At the American Diabetic Association (ADA) 82nd Scientific Sessions, a panel of experts shared some impressive results from a recent trial of the iLet Bionic
As reported by DiaTribe, Dr. Ania Jastreboff, of the Yale University School of Medicine, and colleagues have presented new data which has investigated the effectiveness
At the American Diabetes Association 82nd annual Scientific Sessions, Vertex Pharmaceuticals released new data from a trial of two participants receiving a stem cell-derived beta
The national Children and Young People’s Mental Health (CYPMH) Team at NHS England and Improvement are recruiting four national lived experience partners to work in
